Taiho and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor Read more
Taiho and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor Read more
Moderna Announces Dosing of the First Monoclonal Antibody Encoded by mRNA in a Clinical Trial Read more
FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897 Read more
Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma Read more